Building the Next Generation of TIDES Manufacturing Excellence

The rapid rise of peptide and oligonucleotide therapeutics — driven by breakthroughs in GLP‑1 analogues, RNA‑based medicines, and increasingly complex molecular designs — is pushing manufacturers to rethink how TIDES production can scale responsibly.

Demand is accelerating faster than traditional batch processes can support, prompting a shift toward continuous manufacturing, digital integration, and advanced analytical frameworks that improve speed, reproducibility, and regulatory readiness. At the same time, supply chain fragility and sustainability expectations are reshaping how organizations source raw materials, manage impurities, and design greener, more efficient workflows.

This whitepaper explores how cutting‑edge technologies such as enzymatic synthesis, digital twins, real‑time analytics, and end‑to‑end development models are redefining modern TIDES manufacturing. Readers will gain a clear view of where the field is heading and what it will take to meet growing therapeutic needs with reliability, agility, and environmental responsibility.